OPTION-EMEA Clinical Trial
NCT: NCT07349121 · NOT_YET_RECRUITING
Brief Summary
The OPTION-EMEA post-market study is intended to gather real world clinical data for patients undergoing AF ablation with the FARAPULSE™ Pulsed Field Ablation (PFA) System and subsequent left atrial appendage closure (LAAC) with a WATCHMAN FLX™ Pro or WATCHMAN FLX device during one interventional case. The study will include patients that are clinically indicated for atrial fibrillation (AF) ablation using the FARAPULSE PFA System and for left atrial appendage closure (LAAC) treatment using a WATCHMAN FLX Pro or WATCHMAN FLX device as part of the patient's standard of care determined by their doctor's medical judgement.
Frequently Asked Questions
What is OPTION-EMEA Clinical Trial?
OPTION-EMEA Clinical Trial is a clinical trial registered under NCT07349121. Current status: NOT_YET_RECRUITING.
What is the status of NCT07349121?
The current status of NCT07349121 (OPTION-EMEA Clinical Trial) is: NOT_YET_RECRUITING.
When did OPTION-EMEA Clinical Trial start?
OPTION-EMEA Clinical Trial started on 2026-05.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.